3α,19α-dihydroxyursa-12-en-28-oic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3α,19α-dihydroxyursa-12-en-28-oic acid
• 英文别名: 3-epi-pomolic acid；3-epipomolic acid；pomolic acid；3α,19α-dihydroxy-12-ursen-28-oic acid；(1R,2R,4aS,6aR,6aS,6bR,8aR,10R,12aR,14bS)-1,10-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
• 化学式: C₃₀H₄₈O₄
• 分子量: 472.709
• InChiKey: ZZTYPLSBNNGEIS-QHANTZTQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  34
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3α,19α-dihydroxyursa-12-en-28-oic acid 生成 野鸦椿酸 、 19α-羟基积雪草酸
  参考文献：
  名称：

  Retrovirus protease inhibitors

  摘要：

  揭示了一种复合组合物和治疗逆转录病毒感染的方法。具体来说，已经证明孤立的三萜类化合物对HIV-1具有显著的抑制活性。

  公开号：

  US05916919A1
• 作为产物：
  描述：

  熊果酸 生成 3α,19α-dihydroxyursa-12-en-28-oic acid
  参考文献：
  名称：

  Retrovirus protease inhibitors

  摘要：

  揭示了一种复合组合物和治疗逆转录病毒感染的方法。具体来说，已经证明孤立的三萜类化合物对HIV-1具有显著的抑制活性。

  公开号：

  US05916919A1

文献信息

• Sanguisorbigenin polymer micelle and preparative methods thereof
  申请人：SICHUAN INLU WEITE PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US10646440B2

  公开（公告）日：2020-05-12

  The present invention discloses a sanguisorbigenin polymer micelle, and it is prepared by following raw/auxiliary materials at predetermined weight ratio: 30 parts of sanguisorbigenin and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality evaluation test indicates that only using mPEG-PLA-Phe(Boc) according to the present invention as carrier materials, the quality of sanguisorbigenin polymer micelle prepared is the best, and using other materials can lead to the lowered preparation quality. In pharmacodynamic experiment, compared with the model group, the sanguisorbigenin micelle of the present invention can significantly increase the amounts of WBC, RBC, PLT, NEUT, and HGB in peripheral blood, and the efficacy is obviously better than the original drug of sanguisorbigenin, indicating the sanguisorbigenin polymer micelle has a better treatment and/or prevention effects on bone marrow suppression, and can improve the bioavailability of insoluble drug of sanguisorbigenin.

  本发明公开了一种沙苑子苷元聚合物胶束，它是由以下原辅材料按预定重量比制备而成：沙苑子苷元30份，mPEG-PLA-Phe(Boc)100-5000份。质量评价试验表明，只有使用本发明的 mPEG-PLA-Phe(Boc) 作为载体材料，制备的矢车菊素聚合物胶束的质量才是最好的，使用其他材料会导致制备质量下降。在药效学实验中，与模型组相比，本发明的血浆苷元胶束能显著提高外周血中WBC、RBC、PLT、NEUT、HGB的含量，且疗效明显优于血浆苷元原药，说明血浆苷元聚合物胶束对骨髓抑制有较好的治疗和/或预防作用，并能提高血浆苷元不溶性药物的生物利用度。
• Extracts of blueberries with anti-oxidant and anti-cancer properties
  申请人：——

  公开号：US20030031734A1

  公开（公告）日：2003-02-13

  Compositions and methods for treating and preventing cancer are provided based on administration of a highbush blueberry extract.

  提供了基于高丛蓝莓提取物的治疗和预防癌症的组合物和方法。
• Sanguisorbigenin Polymer Micelle and Preparative Methods Thereof
  申请人：SICHUAN INLU WEITE PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20190142749A1

  公开（公告）日：2019-05-16

  The present invention discloses a sanguisorbigenin polymer micelle, and it is prepared by following raw/auxiliary materials at predetermined weight ratio: 30 parts of sanguisorbigenin and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality evaluation test indicates that only using mPEG-PLA-Phe(Boc) according to the present invention as carrier materials, the quality of sanguisorbigenin polymer micelle prepared is the best, and using other materials can lead to the lowered preparation quality. In pharmacodynamic experiment, compared with the model group, the sanguisorbigenin micelle of the present invention can significantly increase the amounts of WBC, RBC, PLT, NEUT, and HGB in peripheral blood, and the efficacy is obviously better than the original drug of sanguisorbigenin, indicating the sanguisorbigenin polymer micelle has a better treatment and/or prevention effects on bone marrow suppression, and can improve the bioavailability of insoluble drug of sanguisorbigenin.
• US5916919A
  申请人：——

  公开号：US5916919A

  公开（公告）日：1999-06-29
• Retrovirus protease inhibitors
  申请人：Dalhousie University

  公开号：US05916919A1

  公开（公告）日：1999-06-29

  A compound composition and method of treating a retrovirus infection are disclosed. In particular, isolated triterpenes have been shown to have significant inhibitory activity against HIV-1.

  揭示了一种复合组合物和治疗逆转录病毒感染的方法。具体来说，已经证明孤立的三萜类化合物对HIV-1具有显著的抑制活性。